Aphakic and pseudophakic cystoid macular edema

ABSTRACT

To evaluate the effectiveness of medical treatment in patients with aphakic and pseudophakic cystoid macular edema [CME]. A two years prospective study of 25 cases with CME following cataract surgery. Every case underwent full ophthalmological examination and fluorescein fundus angiography. All cases treated by topical non-steroidal anti-inflammatory [Diclofenac 01%] ophthalmic solution 1-2 drops 4 times a day, 10 cases received 0 - [B - hydroxyaethyl] -rutosidea [Venoruton - 300] capsules 1200 mg in two divided oral dose daily for 2 weeks together with the topical diclofenac. Follow-up ranged 6 - 30 months [mean 19 months]. The 25 eyes of 25 patients all unilateral. 21[84.0%] pseudophakic and 4[16.0%] aphakic. Mean duration of CME [10.50 months]. Mean BCVA 0.2. Two groups were identified according to medical treatment, Group A - 15 cases received diclofenac 0.1% alone with 13 [86.7%] improved in a mean period of 8.5 weeks, 2 [13.4%] not improved and 3 [23.1%] with on/off phenomenon. Group B - 10 cases received topical diclofenac 0.1% together with Venoruton 300 capsules 9 [90.0%] improved in a mean 5 weeks, 1 [10.0%] not improved and 1 [11.2%] with on/off phenomenon. Topical non - steroidal anti-inflammatory drugs [Diclofenic 0.1%] ophthalmic solution proved to be beneficial in the prevention and treatment of chronic aphakic and pseudopahkic cystoid macular edema. Oral O - [B - hydroxyaethyl] - rutosidea [Venoruton 300] capsules was beneficial in the present study in augmenting the action of topical diclofenac by shortening the duration of recovery and lowering the rate of recurrence [on/off] phenomenon, but needs further studies